Homocysteine Imbalance: A pathological metabolic marker

Advances in Nutrition

Volumn 3, Issue 6, 2012, Pages 755-762

  Schalinske, Kevin L ^a   Smazal, Anne L ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HOMOCYSTEINE;

GENETIC EPIGENESIS; GENETICS; HEALTH; HUMAN; HYPERHOMOCYSTEINEMIA; METABOLISM; METHYLATION; REVIEW;

BIOLOGICAL MARKERS; EPIGENESIS, GENETIC; HEALTH; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLATION;

EID: 84878098649     PISSN: 21618313     EISSN: 21565376     Source Type: Journal    
DOI: 10.3945/an.112.002758     Document Type: Review

References (98)

1. Kang S-S, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279-98.
2. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003;26:137-46.
3. Newberne PM, Rogers AE. Labile methyl groups and the promotion of cancer. Annu Rev Nutr. 1986;6:407-32.
4. Scott JM, Kirke PN, Weir DG. The role of nutrition in neural tube defects. Annu Rev Nutr. 1990;10:277-95.
5. Williams KT, Schalinske KL. Homocysteine metabolism and its relation to health and disease. Biofactors. 2010;36:19-24.
6. Shenker N, Flanagan JM. Intragenic DNA methylation:implications of this epigenetic mechanism for cancer research. Br J Cancer. 2012;106:248-53.
7. Van den Veyver IB. Genetic effects of methylation diets. Annu Rev Nutr. 2002;22:255-82.
8. Kerr SJ. Competing methyltransferase systems. J Biol Chem. 1972;247:4248-52.
9. Cantoni GL. S-adenosylamino acids thirty years later:1951-1981. In:Usdin E, Borchardt RT, Creveling CR, edtors. The biochemistry of S-adenosylmethionine and related compounds. New York:Macmillan Publishers; 1982. p. 3-10.
10. Cantoni GL, Chiang PK. The role of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase in the control of biological methylations. In:Cavallini D, Gaull GE, Zappia V, editors. Natural sulfur compounds, New York:Plenum Press; 1980. p. 67-80.
11. Mudd SH, Poole JR. Labile methyl balances for normal humans on various dietary regimens. Metabolism. 1975;24:721-35.
12. Mudd SH, Ebert MH, Scriver CR. Labile methyl group balances in the human:the role of sarcosine. Metabolism. 1980;29:707-20.
13. Stead LM, Brosnan JT, Brosnan ME, Vance DE, Jacobs RL. Is it time to reevaluate methyl balance in humans? Am J Clin Nutr. 2006;83:5-10.
14. Wagner C. Biochemical role of folate in cellular metabolism. In:Bailey LB, editors. Folate in health and disease. New York:Marcel Dekker; 1995. p. 23-42.
15. Jencks DA, Matthews RG. Allosteric inhibition of methylenetetrahydrofolate reductase by adenosylmethionine. J Biol Chem. 1987;262:2485-93.
16. Kutzbach C, Stokstad ELR. Feedback inhibition of methylenetetrahydrofolate reductase. Partial purification, properties, and inhibition by S-adenosylmethionine. Biochim Biophys Acta. 1967;139:217-20.
17. Wagner C, Briggs WT, Cook RJ. Inhibition of glycine N-methyltransferase activity by folate derivatives:implications for regulation of methyl group metabolism. Biochem Biophys Res Commun. 1985; 127:746-52.
18. Stead LM, Au KP, Jacobs RL, Brosnan ME, Brosnan JT. Methylation demand and homocysteine metabolism:effects of dietary provision of creatine and guanidinoacetate. Am J Physiol Endocrinol Metab. 2001; 281:E1095-100.
19. Yao ZM, Vance DE. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem. 1988;263:2998-3004.
20. Jacobs RL, Stead LM, Devlin C, Tabas I, Brosnan ME, Brosnan JT, Vance DE. Physiological regulation of phospholipid methylation alters plasma homocysteine in mice. J Biol Chem. 2005;280:28299-305.
21. Noga AA, Zhao Y, Vance DE. An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J Biol Chem. 2002;277:42358-65.
22. Luka Z, Capdevila A, Mato JM, Wagner CA. Glycine N-methyltransferase knockout mouse model for humans with deficiency of this enzyme. Transgenic Res. 2006;15:393-7.
23. Resseguie M, Song J, Nuculescu MD, da Costa KA, Randall TA, Zeisel SH. Phosphatidylethanolamine N-methyltransferase (PEMT) gene expression is induced by estrogen in human and mouse primary hepatocytes. FASEB J. 2007;21:2622-32.
24. Dayal S, Lentz SR. Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler Thromb Vasc Biol. 2008;28:1596-605.
25. Rodionov RN, Lentz SR. The homocysteine paradox. Arterioscler Thromb Vasc Biol. 2008;28:1031-3.
26. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, et al. A candidate genetic risk factor for vascular disease:a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-3.
27. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.
28. Nelen WLDM, Blom HJ, Thomas CMG, Steegers EAP, Boers GHJ, Eskes TKAB. Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutr. 1998;128:1336-41.
29. Devlin AM, Arning E, Bottiglieri T, Faraci FM, Rozen R, Lentz SR. Effect of Mthfr genotype on diet-induced hyperhomocysteinemia and vascular function in mice. Blood. 2004;103:2624-9.
30. Strakova J, Williams KT, Gupta S, Schalinske KL, Kruger WD, Rozen R, Jiracek J, Lucas L, Garrow TA. Dietary intake of S-(α-carboxybutyl)-DL-homocysteine induces hyperhomocysteinemia in rats. Nutr Res. 2010;30:492-500.
31. Teng YW, Mehedint MG, Garrow TA, Zeisel SH. Deletion of betainehomocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem. 2011;286:36258-67.
32. Castro R, Rivera I, Blom HJ, Jakobs C, Travares de Almeida I. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease:an overview. J Inherit Metab Dis. 2006;29:3-20.
33. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia:an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-55.
34. Zaina S, Lindholm MW, Lund G. Nutrition and aberrant DNA methylation patterns in atherosclerosis:more than just hyperhomocysteinemia? J Nutr. 2005;135:5-8.
35. Dayal S, Arning E, Bottiglieri T, Böger RH, Sigmund CD, Faraci FM, Lentz SR. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke. 2004;35:1957-62.
36. Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, Heistad DD, Faraci FM, Lentz SR. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine b-synthase-deficient mice. Circ Res. 2001;88:1203-9.
37. Dayal S, Wilson KM, Leo L, Arning E, Bottiglieri T, Lentz SR. Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood. 2006;108:2237-43.
38. Wilson KM, Lynch CM, Faraci FM, Lentz SR. Effect of mechanical ventilation on carotid artery thrombosis induced by photochemical injury in mice. J Thromb Haemost. 2003;1:2669-74.
39. Woodward M, Rumley A, Rumley C, Lewington S, Morrison CE, Lowe GD. The association between homocysteine and myocardial infarction is independent of age, sex, blood pressure, cholesterol, smoking and markers of inflammation:the Glasgow Myocardial Infarction Study. Blood Coagul Fibrinolysis. 2006;17:1-5.
40. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31-62.
41. De Chiara B, Sedda V, Parolini M, Campolo J, De Maria R, Caruso R, Pizzi G, Disoteo O, Dellanoce C, Corno AR, et al. Plasma total cysteine and cardiovascular risk burden:action and interaction. ScientificWorld Journal. 2012;2012:303654.
42. Blacher J, Czernichow S, Paillard F. Cardiovascular effects of B-vitamins and/or N-3 fatty acids:the Su. Fol. Om3 trial. Int J Cardiol. 2012 Feb 22.
43. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-88.
44. Clarke R, Halsey J, Lewington S, Manson JE, Bønaa KH, Spence JD, Nygård O, Jamison R, Gariano JM, Guarino P, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality:meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010;170:1622-31.
45. den Heijer M, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, Rosendaal FR, Bos GM. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism:a randomized, placebo-controlled, double-blind trial. Blood. 2007;109:139-44.
46. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease:a randomized controlled trial. JAMA. 2007;298:1163-70.
47. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-77.
48. McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr. 2007;86:1563S-8S.
49. McNulty H, Pentieva K, Hoey L, Ward M. Homocysteine, B-vitamins and CVD. Proc Nutr Soc. 2008;67:232-7.
50. Kim BJ, Seo M, Huh J, Kwon C, Kim J, Sung K, Kim B, Kang J. Associations of plasma homocysteine levels with arterial stiffness in prehypertensive individuals. Clin Exp Hypertens. 2011;33:411-7.
51. He L, Zeng H, Fuwang L, Feng J, Liu S, Liu J, Yu J, Mao J, Hong T, Chen A, et al. Homocysteine impairs coronary artery endothelial function by inhibiting tetrabiopterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab. 2010;299:E1061-5.
52. Antoniades C, Shirodaria C, Leeson P, Baarholm O, Van-Assche T, Cunnington C, Pillai R, Ratnatunga C, Tousoulis D, Stefanadis C, et al. MTHFR 677 C>T polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation. 2009;119:2507-15.
53. Hankey G, Eikelbloom P, Dusitanond P, Thom J, Loh K, van Bockxmeer F, Jamrozik K. Homocysteine-lowering treatment with folic acid, cobalamin, and pyroidoxine does not suppress blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with prior TIA or stroke. Stroke. 2005;36:474.
54. Jacobs F, Van Craeyveld E, Muthuramu I, Gordts S, Emmerechts J, Hoylaerts M, Herljgers P, De Geest B. Correction of endothelial dysfunction after selective homocysteine lowering gene therapy reduces arterial thrombogenicity but has no effect on atherogenesis. J Mol Med. 2011;89:1051-8.
55. Fukami A, Adachi H, Hirai Y, EnomotoM, OtsukaM, Nanjo Y, Yoshikawa K, Esaki E, Kumagai E, Ogata K, et al. High levels of plasma homocysteine predicts development of hypertension in a general population:the Tanushimaru study. J Epidemiol Community Health. 2011;65:A245-7.
56. Bogdanski P, Miller-Kasprzak E, Pupek-Musialik D, Jablecka A, Lacinski M, Jagodzinski P, Jakubowski H. Plasma total homocysteine is a determinant of carotid intima-media thickness and circulating endothelial progenitor cells in patients with newly diagnosed hypertension. Clin Chem Lab Med. 2012;50:1107-13.
57. Hofmann MA, Kohl K, Zumbach MS, Borcea V, Bierhaus A, Henkels A, Amira J, Fiehn W, Ziegler R, Wahl P, et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care. 1997;20:1880-6.
58. Poirier LA, Brown AT, Fink LM, Wise CK, Randolph CJ, Delongchamp RR, Fonseca VA. Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathy. Metabolism. 2001;50:1014-8.
59. Robillon JF, Canivet B, Candito M, Sadoul JL, Jullien D, Morand P, Chambon P, Freychet P. Type 1 diabetes mellitus and homocyst(e) ine. Diabete Metab. 1994;20:494-6.
60. Jacobs RL, House JD, Brosnan ME, Brosnan JT. Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes. 1998;47:1967-70.
61. Jacobs RL, Steads LM, Brosnan ME, Brosnan JT. Hyperglucagonemia in rats results in decreased plasma homocysteine and increased flux through the transsulfuration pathway in liver. J Biol Chem. 2001;276:43740-7.
62. Nieman KM, Hartz CS, Szegedi SS, Garrow TA, Sparks JD, Schalinske KL. Folate status modulates the induction of hepatic glycine Nmethyltransferase and homocysteine metabolism in diabetic rats. Am J Physiol Endocrinol Metab. 2006;291:E1235-42.
63. Nieman KM, Rowling MJ, Garrow TA, Schalinske KL. Modulation of methyl group metabolism by streptozotocin-induced diabetes and alltrans-retinoic acid. J Biol Chem. 2004;279:45708-12.
64. Ratnam S, Maclean KN, Jacobs RL, Brosnan ME, Kraus JP, Brosnan JT. Hormonal regulation of cystathionine b-synthase expression in liver. J Biol Chem. 2002;277:42912-8.
65. Ratnam S, Wijekoon EP, Hall B, Garrow TA, Brosnan ME, Brosnan JT. Effects of diabetes and insulin on betaine-homocysteine S-methyltransferase expression in rat liver. Am J Physiol Endocrinol Metab. 2006;290:E933-39.
66. Wang L, Jhee K-H, Hua X, DiBello PM, Jacobsen DW, Kruger WD. Modulation of cystathionine b-synthase level regulates total serum homocysteine in mice. Circ Res. 2004;94:1318-24.
67. Hartz CS, Nieman KM, Jacobs RL, Vance DE, Schalinske KL. Hepatic phosphatidyl-ethanolamine N-methyltransferase expression is increased in diabetic rats. J Nutr. 2006;136:3005-9.
68. Nieman KM, Schalinske KL. Insulin abrogates perturbation of methyl group and homocysteine metabolism in diabetic rats. Am J Physiol Endocrinol Metab. 2011;301:E560-5.
69. Tessari P, Coracina A, Kiwanuka E, Vedovato M, Vettore M, Valerio A, Zaramella M, Garibotto G. Effects of insulin on methionine and homocysteine kinetics in type 2 diabetes with nephropathy. Diabetes. 2005; 54:2968-76.
70. Williams KT, Schalinske KL. Tissue-specific alterations of methyl group metabolism and DNA hypermethylation in the Zucker (type 2) diabetic fatty (ZDF) rat. Diabetes Metab Res Rev. 2012;28:123-31.
71. Danese S, Sgambato A, Papa A, Scaldaferri F, Pola R, Sans M, Lovecchio M, Gasbarrini G, Cittadini A, Gasbarrini A. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol. 2005;100:886-95.
72. Munjal C, Givvimani S, Qipshidze N, Tyagi N, Falcone JC, Tyagi SC. Mesenteric vascular remodeling in hyperhomocysteinemia. Mol Cell Biochem. 2011;348:99-108.
73. Givvimani S, Munjal C, Narayanan N, Aqil F, Tyagi G, Metreveli N, Tyagi SC. Hyperhomocysteinemia decreases intestinal motility leading to constipation. Am J Physiol Gastrointest Liver Physiol. 2012;303:G281-90.
74. Wiernicki I, Millo B, Safranow K, Gorecka-Szyld B, Gutowski P. MMP-9, homocysteine and CRP circulating levels are associated with intraluminal thrombus thickness of abdominal aortic aneurysms:new implication of the old biomarkers. Dis Markers. 2011;31:67-74.
75. Chowers Y, Sela BA, Holland R, Fidder H, Simoni FB, Bar-Meir S. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am J Gastroenterol. 2000;95:3498-502.
76. Oussalah A, Guéant JL, Peyrin-Biroulet L. Meta-analysis:hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther. 2011;34:1173-84.
77. Schulpis KH, Karikas GA, Georgala S, Michas T, Tsakiris S. Elevated plasma homocysteine levels in patients on isotretinoin therapy for cystic acne. Int J Dermatol. 2001;40:33-6.
78. Thakrar BT, Robinson NJ. Isotretinoin use and the risk of inflammatory bowel disease. Am J Gastroenterol. 2011;106:1000-2, author reply 1002-3.
79. Elshorbagy AK, Gjesdal CG, Nurk E, Tell GS, Ueland PM, Nygård O, Tverdal A, Vollset SE, Smith AD, Refsum H. Cysteine, homocysteine and bone mineral density:a role for body composition? Bone. 2009; 44:954-8.
80. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350:2033-41.
81. Kim DJ, Koh JM, Lee O, Kim NJ, Lee YS, Kim YS, Park JY, Lee KU, Kim GS. Homocysteine enhances apoptosis in human bone marrow stromal cells. Bone. 2006;39:582-90.
82. Herrmann M, Tami A, Wildemann B, Wolny M, Wagner A, Schorr H, Taban-Shomal O, Umanskaya N, Ross S, Garcia P, et al. Hyperhomocysteinemia induces a tissue specific accumulation of homocysteine in bone by collagen binding and adversely affects bone. Bone. 2009;44:467-75.
83. Thaler R, Spitzer S, RumplerM, Fratzl-Zelman N, Klaushofer K, Paschalis E, Varga F. Differential effects of homocysteine and beta aminopropionitrile on preosteoblastic MC3T3-E1 cells. Bone. 2010;46:703-9.
84. Tyagi N, Vacek T, Fleming J, Vacek J, Tyagi S. Hyperhomocysteinemia reduces bone blood flow. Vasc Health Risk Manag. 2011;7:31-5.
85. Herrmann M, Umanskaya N, Traber L, Schmidt-Gayk H, Menke W, Lanzer G, Lenhart M, Peter Schmidt J, Herrmann W. The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients:a 1-year double blind placebo controlled trial. Clin Chem Lab Med. 2007;45:1785-92.
86. Gu P, Defina LF, Leonard D, John S, Weiner MF, Brown ES. Relationship between serum homocysteine levels and depressive symptoms:the Cooper Center Longitudinal Study. J Clin Psychiatry. 2012;73:691-5.
87. Gariballa S. Testing homocysteine-induced neurotransmitter deficiency, and depression of mood hypothesis in clinical practice. Age Ageing. 2011;40:702-5.
88. Jankovic J. Parkinson's disease:clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368-76.
89. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB, Jr., Bottiglieri T, Diaz-Arrastia R. Elevated plasma homocysteine level in patients with Parkinson disease:motor, affective, and cognitive associations. Arch Neurol. 2004;61:865-8.
90. O'Suilleabhain PE, Oberle R, Bartis C, Dewey RB, Bottiglieri T, Diaz-Arrastia R. Clinical course in Parkinson's disease with elevated homocysteine. Parkinsonism Relat Disord. 2006;12:103-7.
91. Lee SH, Kim MJ, Kim BJ, Kim SR, Chun S, Ryu JS, Kim GS, Lee MC, Koh JM, Chung SJ. Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease. Mov Disord. 2010;25:332-40.
92. Evatt ML. Nutritional therapies in Parkinson's disease. Curr Treat Options Neurol. 2007;9:198-204.
93. Nascimento CM, Stella F, Garlipp CR, Santos RF, Gobbi S, Gobbi LT. Serum homocysteine and physical exercise in patients with Parkinson's disease. Psychogeriatrics. 2011;11:105-12.
94. Zylberstein DE, Lissner L, Bjorkelund C, Mehlig K, Thelle D, Gustafson D, Ostling S, Waeren M, Guo X, Skoog I. Midlife homocysteine and late-life dementia in women:a prospective population study. Neurobiol Aging. 2011;32:380-6
95. Oulhaj A, Refsum H, Beaumont H, Williams J, King E, Jacoby R, Smith A. Homocysteine as a predictor of cognitive decline in Alzheimer's disease. Int J Geriatr Psychiatry. 2010;25:82-90.
96. Chen CS, Chou M, Yeh Y, Yang Y, Lai C, Uen C, Liu C, Liao Y. Plasma homocysteine levels and major depressive disorders in Alzheimer's disease. Am J Geriatr Psychiatry. 2010;18:1045-8.
97. Zhuo JM, Pratico D. Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease. FASEB J. 2010;24:3895-902.
98. Kwok T, Lee J, Law C, Pan P, Yung C, Choi K, Lam L. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clin Nutr. 2011;30:297-302.